Pharma Focus Asia

Drug Safety Evaluation, Third Edition

Drug Safety Evaluation, Third Edition

Pages: 968

Publisher: Wiley

Year of Publication: 2016

Author(s) : Shayne Cox Gad

Book Description:

This practical guide presents a road map for safety assessment as an integral part of the development of new drugs and therapeutics.

Drug Safety Evaluation, 3rd Edition helps readers solve scientific, technical, and regulatory issues in preclinical safety assessment and early clinical drug development. It also  explains scientific and philosophical bases for evaluation of specific concerns – including local tissue tolerance, target organ toxicity and carcinogenicity, developmental toxicity, immunogenicity, and immunotoxicity.

This book contains a vast coverage of the development of new small and large molecules, generics, 505(b)(2) route NDAs, and biosimilars as well as revision of material to reflect new drug products (small synthetic, large proteins and cells, and tissues), harmonized global and national regulations, and new technologies for safety evaluation.

This is the latest edition to a priceless series of helpful guides and along with its most recent instalment, Drug Safety and Evaluation brings nearly twenty percent of all-new  and thoroughly updates existing content from the last edition.

http://as.wiley.com/WileyCDA/WileyTitle/productCd-1119097398.html

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024